Cargando…

Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses

BACKGROUND: Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood. METHODS: For a comprehensive analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Tao, Li, Keyu, Niu, Nan, Shao, Yingkuan, Ding, Ding, Thomas, Dwayne L., Jing, Hao, Fujiwara, Kenji, Hu, Haijie, Osipov, Arsen, Yuan, Chunhui, Wolfgang, Christopher L., Thompson, Elizabeth D., Anders, Robert A., He, Jin, Mou, Yiping, Murphy, Adrian G., Zheng, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962046/
https://www.ncbi.nlm.nih.gov/pubmed/35346322
http://dx.doi.org/10.1186/s13045-022-01253-z
_version_ 1784677714172575744
author Xia, Tao
Li, Keyu
Niu, Nan
Shao, Yingkuan
Ding, Ding
Thomas, Dwayne L.
Jing, Hao
Fujiwara, Kenji
Hu, Haijie
Osipov, Arsen
Yuan, Chunhui
Wolfgang, Christopher L.
Thompson, Elizabeth D.
Anders, Robert A.
He, Jin
Mou, Yiping
Murphy, Adrian G.
Zheng, Lei
author_facet Xia, Tao
Li, Keyu
Niu, Nan
Shao, Yingkuan
Ding, Ding
Thomas, Dwayne L.
Jing, Hao
Fujiwara, Kenji
Hu, Haijie
Osipov, Arsen
Yuan, Chunhui
Wolfgang, Christopher L.
Thompson, Elizabeth D.
Anders, Robert A.
He, Jin
Mou, Yiping
Murphy, Adrian G.
Zheng, Lei
author_sort Xia, Tao
collection PubMed
description BACKGROUND: Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood. METHODS: For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data. RESULTS: This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B(+)CD8(+) effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1(−)EOMES(−)CD8(+) effector T cells are associated with long-term survival. However, only the density of PD-1(−)EOMES(−)CD8(+) T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1(+) tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1(+) M1 or M2, PD-L1(−) M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1(−) M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1(+) tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion. CONCLUSIONS: This study suggests that the densities of Granzyme-B(+)CD8(+) effector T cells and non-exhausted PD-1(−)EOMES(−)CD8(+) T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1(+) tumor-associated macrophages as the immunotherapy for cholangiocarcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01253-z.
format Online
Article
Text
id pubmed-8962046
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89620462022-03-30 Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses Xia, Tao Li, Keyu Niu, Nan Shao, Yingkuan Ding, Ding Thomas, Dwayne L. Jing, Hao Fujiwara, Kenji Hu, Haijie Osipov, Arsen Yuan, Chunhui Wolfgang, Christopher L. Thompson, Elizabeth D. Anders, Robert A. He, Jin Mou, Yiping Murphy, Adrian G. Zheng, Lei J Hematol Oncol Research BACKGROUND: Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood. METHODS: For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data. RESULTS: This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B(+)CD8(+) effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1(−)EOMES(−)CD8(+) effector T cells are associated with long-term survival. However, only the density of PD-1(−)EOMES(−)CD8(+) T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1(+) tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1(+) M1 or M2, PD-L1(−) M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1(−) M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1(+) tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion. CONCLUSIONS: This study suggests that the densities of Granzyme-B(+)CD8(+) effector T cells and non-exhausted PD-1(−)EOMES(−)CD8(+) T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1(+) tumor-associated macrophages as the immunotherapy for cholangiocarcinoma. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01253-z. BioMed Central 2022-03-28 /pmc/articles/PMC8962046/ /pubmed/35346322 http://dx.doi.org/10.1186/s13045-022-01253-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xia, Tao
Li, Keyu
Niu, Nan
Shao, Yingkuan
Ding, Ding
Thomas, Dwayne L.
Jing, Hao
Fujiwara, Kenji
Hu, Haijie
Osipov, Arsen
Yuan, Chunhui
Wolfgang, Christopher L.
Thompson, Elizabeth D.
Anders, Robert A.
He, Jin
Mou, Yiping
Murphy, Adrian G.
Zheng, Lei
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
title Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
title_full Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
title_fullStr Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
title_full_unstemmed Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
title_short Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
title_sort immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962046/
https://www.ncbi.nlm.nih.gov/pubmed/35346322
http://dx.doi.org/10.1186/s13045-022-01253-z
work_keys_str_mv AT xiatao immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT likeyu immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT niunan immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT shaoyingkuan immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT dingding immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT thomasdwaynel immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT jinghao immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT fujiwarakenji immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT huhaijie immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT osipovarsen immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT yuanchunhui immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT wolfgangchristopherl immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT thompsonelizabethd immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT andersroberta immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT hejin immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT mouyiping immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT murphyadriang immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses
AT zhenglei immunecellatlasofcholangiocarcinomasrevealsdistincttumormicroenvironmentsandassociatedprognoses